As the pace of change in the pharma and biotech industry continues to accelerate, companies are increasingly relying on CDMOs to help them meet complex challenges and capitalize on fast-evolving opportunities. CDMOs have responded in a variety of ways—adding specialized services via mergers and acquisition, making forays into biologics, or expanding their capabilities across the drug lifecycle.
In all of these cases, CDMOs face the challenge of integrating novel technologies—technologies that are either new to the CDMO or new to the industry—to deliver cost-effective innovation to the market. But developing and applying novel technologies can be a costly and complex undertaking. Roadblocks and setbacks are an inevitable frustration of doing something new. How a CDMO responds to the unexpected can determine the success or failure of a project. Read more >